The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology (한방안이비인후피부과학회지)

The Society of Korean Medicine Ophthalmology, Otolaryngology & Dermatology (대한한방안이비인후피부과학회)
권호 표지
DOI QR코드

DOI QR Code

The Study on the Pityriasis Rosea in Oriental-Western Medicine

장미색비강진에 대한 동서의학적 고찰

  • Lee, Kyou-Young (Department of Ophthalmology, Otolaryngology & Dermatology, College of Korean medicine, Sangji University)
  • 이규영 (상지대학교 한의과대학 안이비인후피부과학교실)
  • Received : 2022.09.07
  • Accepted : 2022.11.08
  • Published : 2022.11.25
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : In this study, we aimed to analyze the latest knowledge of pityriasis rosea(PR) through oriental-western medical review on PR. Methods : We searched Pubmed, CNKI, and OASIS to select papers related to the cause, mechanism, diagnosis, classification, treatment, and herbal treatment of PR. Results : The results are as follows. 1. Although the exact cause of PR is not known, it has recently been found that reactivation of latent human herpesvirus-6 and human herpesvirus-7 infection is a possible etiology. Most patients require emollients, antihistamines, topical steroids, and macrolides. Acyclovir, and narrow-band UVB therapy are also used. 2. The cause and mechanism of PR in Chinese and Korean medicine can be mainly summarized as wind-heat, blood heat, and blood deficiency and wind-dryness. Most of the herbal medicine used have the effects of clearing heat, cooling the blood, detoxifying, dispelling wind, relieving itching, nourishing blood, and moistening dryness. Conclusions : In Chinese and Korean medicine, it is necessary to organize the representative prescriptions according to pattern identification, and it is also necessary to study the atypical types of PR and its treatment methods. It is thought that research on oriental and western combination therapy should be continuously conducted, and efforts to develop Korean medicine formulations are needed to revitalize clinical research in Korea.

Keywords

References

  1. The society of Korean medicine Ophthalmology, Otolaryngology & Dermatology. Text of Traditional Korean Dermatology & Surgery. Seoul:Globooks. 2022:97-100.
  2. Kwak JY, Lee YH, Shin SH, Ahn JH, Kim MH, Choi IH. Three Cases of Pityriasis Rosea in Child treated with Eunkyo-san. J Korean Med Ophthalmol Otolaryngol Dermatol. 2017;30(2):155-64.
  3. Jung MY, Kim MJ, Kim DS, Park YH, Park SY, Kim JH, et al. Pityriasis rosea: Report of 1 Case Treated by Oriental Medicine. J Korean Med Ophthalmol Otolaryngol Dermatol. 2007;20(3):268-75.
  4. Jin HS, Lim HY, Ko WS, Yoon HJ. Herbal Medicine for The Treatment of Pityriasis rosea: A Systematic Review and Meta-analysis. J Korean Med Ophthalmol Otolaryngol Dermatol. 2021;34(4):117-33.
  5. Veraldi S, Spigariolo CB. Pityriasis rosea and COVID-19. J Med Virol. 2021;93(7):4068. https://doi.org/10.1002/jmv.26679
  6. Drago F, Ciccarese G, Rebora A, Parodi A. Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19. J Med Virol. 2021;93(4):1850, 1851.
  7. Dursun R, Temiz SA. The clinics of HHV-6 infection in COVID-19 pandemic: pityriasis rosea and Kawasaki disease. Dermatol Ther. 2020;33(4):e13730.
  8. Ciccarese G, Parodi A, Drago F. SARS-CoV-2 as possible inducer of viral reactivations. Dermatol Ther. 2020;33(6):e13878.
  9. Brambilla L, Maronese CA, Tourlaki A, Veraldi S. Herpes Zoster following COVID-19: a report of three cases. Eur J Dermatol. 2020;30(6):754-6. https://doi.org/10.1684/ejd.2020.3924
  10. Marcantonio-Santa Cruz OY, Vidal-Navarro A, Pesque D, Gimenez-Arnau AM, Pujol RM, Martin-Ezquerra G. Pityriasis rosea developing after COVID-19 vaccination. J Eur Acad Dermatol Venereol. 2021;35(11):e721,e722.
  11. Drago F, Ciccarese G, Javor S, Parodi A. Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature. J Eur Acad Dermatol Venereol. 2016;30:544,545.
  12. Gay JT, Huq M, Gross GP. Herald Patch. Treasure Island (FL):StatPearls Publishing [Internet]. 2022:1-6.
  13. Engelmann I, Ogiez J, Ogiez L, Alidjinou EK, Lazrek M, Dewilde A, et al. Relapsing Pityriasis Rosea With HHV-7 Reactivation in an 11-Year-Old Girl. Pediatrics. 2018;141(5):e20173179. https://doi.org/10.1542/peds.2017-3179
  14. Alame MM, Chamsy DJ, Zaraket H. Pityriasis rosea-like eruption associated with ondansetron use in pregnancy. Br J Clin Pharmacol. 2018;84(5):1077-80. https://doi.org/10.1111/bcp.13560
  15. Litchman G, Nair PA, Le JK. Pityriasis Rosea. Treasure Island (FL):StatPearls Publishing[Internet]. 2022:1-7.
  16. Gangemi S, Minciullo PL, Guarneri F, Cristani M, Arcoraci T, Spatari G, et al. Increased serum levels of interleukin-22 in patients affected by pityriasis rosea. J Eur Acad Dermatol Venereol. 2009;23:858,859.
  17. Gangemi S, Cannavo SP, Guarneri F, Merendino RA, Stur-niolo GC, Minciullo PL, et al. The CX3C-chemokine frac- talkine (CX3CL1) is detectable in serum of patients affected by active pityriasis rosea. J Eur Acad Dermatol Venereol. 2006;20:1366, 1367.
  18. El-Ela MA, El-Komy M, Hay RA, Hegazy R, Sharobim A, Rashed L, et al. Higher Expression of Toll-like Receptors 3, 7, 8, and 9 in Pityriasis Rosea. Journal of Pathology and Translational Medicine. 2017;51:148-51. https://doi.org/10.4132/jptm.2016.09.09
  19. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol. 2007;7:179-90. https://doi.org/10.1038/nri2038
  20. Wagner H. The immunobiology of the TLR9 subfamily. Trends Immunol. 2004;25: 381-6. https://doi.org/10.1016/j.it.2004.04.011
  21. Trayes KP, Savage K, Studdiford JS. Annular Lesions: Diagnosis and Treatment. Am Fam Physician. 2018;98(5):283-91.
  22. Rodriguez-Zuniga M, Torres N, GarciaPerdomo H. Effectiveness of acyclovir in the treatment of pityriasis rosea. A systematic review and meta-analysis. An Bras Dermatol. 2018;93(5):686-95. https://doi.org/10.1590/abd1806-4841.20187252
  23. Sonthalia S, Kumar A, Zawar V, Priya A, Yadav P, Srivastava S, et al. Double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of short-course low-dose oral prednisolone in pityriasis rosea. J Dermatolog Treat. 2018;29(6):617-22. https://doi.org/10.1080/09546634.2018.1430302
  24. Chuh AA. Diagnostic criteria for pityriasis rosea: A prospective case control study for assessment of validity. J Eur Acad Dermatol Venereol. 2003;17:101-3. https://doi.org/10.1046/j.1468-3083.2003.00519_4.x
  25. Zawar V, Chuh A. Applicability of proposed diagnostic criteria of pityriasis rosea: Results of a prospective case-control study in India. Indian J Dermatol. 2013;58:439-42. https://doi.org/10.4103/0019-5154.119950
  26. Mahajan K, Relhan V, Relhan AK, Garg VK. Pityriasis Rosea: An Update on Etiopathogenesis and Management of Difficult Aspects. Indian J Dermatol. 2016;61(4):375-84. https://doi.org/10.4103/0019-5154.185699
  27. Drago F, Broccolo F, Rebora A. Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology. J Am Acad Dermatol. 2009;61:303-18. https://doi.org/10.1016/j.jaad.2008.07.045
  28. Drago F, Vecchio F, Rebora A. Use of high-dose acyclovir in pityriasis rosea. J Am Acad Dermatol. 2006;54:82-5. https://doi.org/10.1016/j.jaad.2005.06.042
  29. Drago F, Ciccarese G, Rebora A, Parodi A. Relapsing pityriasis rosea. Dermatology 2014;229:316-8. https://doi.org/10.1159/000363568
  30. Drago F, Broccolo F, Ciccarese G, Rebora A, Parodi A. Persistent pityriasis rosea: an unusual form of pityriasis rosea with persistent active HHV-6 and HHV-7 infection. Dermatology. 2015;230:23-6. https://doi.org/10.1159/000368352
  31. Vidimos AT, Camisa C. Tongue and cheek: oral lesions in pityriasis rosea. Cutis. 1992;50:276-80.
  32. Bjornberg A, Hellgren L. Pityriasis rosea. A statistical, clinical, and laboratory investigation of 826 patients and matched healthy controls. Acta Derm Venereol Suppl (Stockh). 1962;42(suppl 50):1-68.
  33. Drago F, Ciccarese G, Broccolo F, Cozzani E, Parodi A. Pityriasis rosea in children: clinical features and laboratory investigations. Dermatology. 2015;231:9-14. https://doi.org/10.1159/000381285
  34. Hall CB, Long CE, Schnabel KC, Caserta MT, McIntyre KM, Costanzo MA, Knott A, Dewhurst S, Insel RA, Epstein LG. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med. 1994;331:432-8. https://doi.org/10.1056/NEJM199408183310703
  35. Corson EF, Luscombe HA. Coincidence with pityriasis rosea with pregnancy. AMA Arch Derm Syphilol. 1950;62:562-4. https://doi.org/10.1001/archderm.1950.01530170088012
  36. Drago F, Broccolo F, Zaccaria E, Malnati M, Cocuzza C, Lusso P, et al. Pregnancy outcome in patients with pityriasis rosea. J Am Acad Dermatol. 2008;58:S78-83. https://doi.org/10.1016/j.jaad.2007.05.030
  37. Drago F, Broccolo F, Javor S, Drago F, Rebora A, Parodi A. Evidence of human herpesvirus-6 and 7 reactivation in miscarrying women with pityriasis rosea. J Am Acad Dermatol. 2014;71:198,199.
  38. Drago F, Ciccarese G, Rebora A, Parodi A. Pityriasis rosea and pityriasis rosea-like eruption: can they be distinguished? J Dermatol. 2014;41:864,865.
  39. Drago F, Broccolo F, Agnoletti A, Drago F, Rebora A, Parodi A. Pityriasis rosea and pityriasis rosea-like eruptions. J Am Acad Dermatol. 2014;70:196.
  40. Drago F, Ciccarese G, Javor S, Parodi A. Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature. J Eur Acad Dermatol Venereol. 2016;30:544,545.
  41. Krishnamurthy K, Walker A, Gropper CA, Hoffman C. To treat or not to treat? Management of guttate psoriasis and pityriasis rosea in patients with evidence of group A Streptococcal infection. J Drugs Dermatol. 2010;9(3):241-50.
  42. Jairath V, Mohan M, Jindal N, Gogna P, Syrty C, Monnappa PM, et al. Narrowband UVB phototherapy in pityriasis rosea. Indian Dermatol Online J. 2015;6:326-9. https://doi.org/10.4103/2229-5178.164480
  43. Yun GJ, Pan F. Clinical application of Yinxieling ointment and pricking cupping bloodletting in treating pityriasis rosea. China's Naturopathy. 2018;9:39-41.
  44. Zhang JY. Clinical Observation on Treatment of Blood Heat and Exuberant Wind Type Pityriasis Rosea with Liangjie Xiaozhen Decoction. Master's Thesis of Heilongjiang Academy of Traditional Chinese Medicine. 2019:1-37.
  45. Zheng ZG. Clinical Observation on Yinqiao Powder Combined with Western Medicine in the Treatment of Pityriasis Rosea. Chinese Medicine Modern Distance Education of China. 2020;4:250-2.
  46. Zhao WC. Clinical study on the treatment of pityriasis rosea with wind-heat and skin retaining method by soothing wind and heat. Master's Thesis of Changchun university of Chinese medicine. 2021:1-58.
  47. Jing C. The clinical observation of Tuizhen Xiaoban Decoction in the treatment of wind-heat and blood dry type pityriasis rosea. Master's Thesis of Heilongjiang University of Traditional Chinese Medicine. 2019:1-39.
  48. Geo JS, Liu TF, Wang JF. Clinical observation of 24 cases of pityriasis rosea with blood deficiency and wind-dryness type treated with Dangguiyinzi modified and subtracted combined with auricular point pressure method. The Journal of Medical Theory and Practice. 2022;3:443-5.
  49. Liu G. Clinical Observation on 12 Cases of Refractory Pityriasis Rosea Treated by Integrated Traditional Chinese and Western Medicine. China's Naturopathy. 2019;3:60,61.
  50. Chen JH, He XY, Wang X, Qu XF. Clinical study on the treatment of wind-heat and blood-dry type pityriasis rosea with integrated traditional Chinese and western medicine. Chinese Manipulation & Rehabilitation Medicine. 2019;16:34-6.
  51. Wang YQ, Bai MJ, Wu YN, Liu BX, Wang XY, Yu XJ. Research progress on diagnosis and treatment of pityriasis rosea by integrated traditional Chinese and western medicine. Shandong Journal of Traditional Chinese Medicine. 2019;4:384-9.
  52. The Minjok Medicine News. 2012[cited 2022 AUGUST 2]. Available from: URL:http://www.mjmedi.com/news/articleView.html?idxno=23863